EIF2A and cancer: Experiments with the pharmacological inhibitor of eIF2α dephosphorylation—salubrinal—as well as with the phosphomimetic S51D and the non-phosphorylatable S51A variants of eIF2α showed that increased phosphorylation of eIF2α –in and of itself—sensitizes cancer cells to ABT-888.